Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial
© 2023 The Authors. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion..
BACKGROUND AND OBJECTIVES: The efficacy of COVID-19 convalescent plasma (CP) associates with high titres of antibodies. ConPlas-19 clinical trial showed that CP reduces the risk of progression to severe COVID-19 at 28 days. Here, we aim to study ConPlas-19 donors and characteristics that associate with high anti-SARS-CoV-2 antibody levels.
MATERIALS AND METHODS: Four-hundred donors were enrolled in ConPlas-19. The presence and titres of anti-SARS-CoV-2 antibodies were evaluated by EUROIMMUN anti-SARS-CoV-2 S1 IgG ELISA.
RESULTS: A majority of 80.3% of ConPlas-19 donor candidates had positive EUROIMMUN test results (ratio ≥1.1), and of these, 51.4% had high antibody titres (ratio ≥3.5). Antibody levels decline over time, but nevertheless, out of 37 donors tested for an intended second CP donation, over 90% were still EUROIMMUN positive, and nearly 75% of those with high titres maintained high titres in the second sample. Donors with a greater probability of developing high titres of anti-SARS-CoV-2 antibodies include those older than 40 years of age (RR 2.06; 95% CI 1.24-3.42), with more than 7 days of COVID-19 symptoms (RR 1.89; 95% CI 1.05-3.43) and collected within 4 months from infection (RR 2.61; 95% CI 1.16-5.90). Male donors had a trend towards higher titres compared with women (RR 1.67; 95% CI 0.91-3.06).
CONCLUSION: SARS-CoV-2 CP candidate donors' age, duration of COVID-19 symptoms and time from infection to donation associate with the collection of CP with high antibody levels. Beyond COVID-19, these data are relevant to inform decisions to optimize the CP donor selection process in potential future outbreaks.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:119 |
|---|---|
| Enthalten in: |
Vox sanguinis - 119(2024), 1 vom: 17. Jan., Seite 27-33 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Romera Martínez, Irene [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-SARS-CoV-2 |
|---|
| Anmerkungen: |
Date Completed 24.01.2024 Date Revised 24.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/vox.13561 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364780312 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364780312 | ||
| 003 | DE-627 | ||
| 005 | 20240124232000.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/vox.13561 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1269.xml |
| 035 | |a (DE-627)NLM364780312 | ||
| 035 | |a (NLM)37986640 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Romera Martínez, Irene |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2024 | ||
| 500 | |a Date Revised 24.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion. | ||
| 520 | |a BACKGROUND AND OBJECTIVES: The efficacy of COVID-19 convalescent plasma (CP) associates with high titres of antibodies. ConPlas-19 clinical trial showed that CP reduces the risk of progression to severe COVID-19 at 28 days. Here, we aim to study ConPlas-19 donors and characteristics that associate with high anti-SARS-CoV-2 antibody levels | ||
| 520 | |a MATERIALS AND METHODS: Four-hundred donors were enrolled in ConPlas-19. The presence and titres of anti-SARS-CoV-2 antibodies were evaluated by EUROIMMUN anti-SARS-CoV-2 S1 IgG ELISA | ||
| 520 | |a RESULTS: A majority of 80.3% of ConPlas-19 donor candidates had positive EUROIMMUN test results (ratio ≥1.1), and of these, 51.4% had high antibody titres (ratio ≥3.5). Antibody levels decline over time, but nevertheless, out of 37 donors tested for an intended second CP donation, over 90% were still EUROIMMUN positive, and nearly 75% of those with high titres maintained high titres in the second sample. Donors with a greater probability of developing high titres of anti-SARS-CoV-2 antibodies include those older than 40 years of age (RR 2.06; 95% CI 1.24-3.42), with more than 7 days of COVID-19 symptoms (RR 1.89; 95% CI 1.05-3.43) and collected within 4 months from infection (RR 2.61; 95% CI 1.16-5.90). Male donors had a trend towards higher titres compared with women (RR 1.67; 95% CI 0.91-3.06) | ||
| 520 | |a CONCLUSION: SARS-CoV-2 CP candidate donors' age, duration of COVID-19 symptoms and time from infection to donation associate with the collection of CP with high antibody levels. Beyond COVID-19, these data are relevant to inform decisions to optimize the CP donor selection process in potential future outbreaks | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a anti-SARS-CoV-2 | |
| 650 | 4 | |a convalescent plasma | |
| 650 | 4 | |a donors | |
| 650 | 4 | |a passive immunotherapy | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Avendaño-Solá, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Villegas Da Ros, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Bosch Llobet, Alba |e verfasserin |4 aut | |
| 700 | 1 | |a García Erce, José Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a González Fraile, María Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Guerra Domínguez, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Vicuña Andrés, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Anguita Velasco, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a González Rodríguez, Victoria Paz |e verfasserin |4 aut | |
| 700 | 1 | |a Contreras, Enric |e verfasserin |4 aut | |
| 700 | 1 | |a Urcelay Uranga, Sabin |e verfasserin |4 aut | |
| 700 | 1 | |a Pajares Herraiz, Ángel Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez-Marco, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Ojea Pérez, Ana María |e verfasserin |4 aut | |
| 700 | 1 | |a Arroyo Rodríguez, José Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Olmeda, Mayte |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos-Martínez, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Velasco-Iglesias, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Bueno Cabrera, José Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Duarte, Rafael F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vox sanguinis |d 1952 |g 119(2024), 1 vom: 17. Jan., Seite 27-33 |w (DE-627)NLM000095028 |x 1423-0410 |7 nnns |
| 773 | 1 | 8 | |g volume:119 |g year:2024 |g number:1 |g day:17 |g month:01 |g pages:27-33 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/vox.13561 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 119 |j 2024 |e 1 |b 17 |c 01 |h 27-33 | ||